MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma
The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...
Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response
German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health...
3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first...
BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics...
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...
VectorBuilder Partners with Sino Biological to Boost Global Biological Reagents Market
VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial...
CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development
CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with...
Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Lepu Biotechnology’s Pancreatic Cancer Drug Earns Orphan Drug Status from FDA
Lepu Biotechnology Co., Ltd (HKG: 2157), a Chinese pharmaceutical company, has announced that it has...
AbelZeta Pharma Expands Janssen Partnership to Include Commercial Rights in China
AbelZeta Pharma Inc., a Sino-US biotechnology company with operations in Rockville, Maryland, and Shanghai, China,...
AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their...
Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment
The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...
Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast
Pfizer Inc. (NYSE: PFE) has secured all necessary regulatory approvals to finalize its $43 billion...
Fosun Pharmaceutical and Insightec Form JV to Bring MRgFUS Brain Therapy to China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to establish a joint...
Jiangsu Initiates Sunshine Procurement Round for Medical Consumables with 46 Products
The Jiangsu Public Resource Trading Platform has announced a new round of sunshine online procurement...
HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO
HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public...
MicroPort MedBot’s R-ONE Vascular Intervention Robot Approved by China’s NMPA
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received market...
Eisai and BioArctic Set December Launch for Alzheimer’s Drug Leqembi in Japan
Eisai (TYO: 4523) and BioArctic (STO: BIOA-B) have announced the launch of Leqembi (lecanemab) in...
Abbisko Therapeutics’ Pimicotinib Earns FDA Fast-Track Status for TGCT Treatment
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology firm, has announced that its colony...
China’s 2023 NRDL Expands Coverage with 126 New Drugs, Aims for Savings and Accessibility
The National Healthcare Security Administration (NHSA) has released the finalized National Reimbursement Drug List (NRDL)...